Toutes les photos(1)

Key Documents

COO/COA

I0361000

Ipratropium bromide impurity B

Name: Ipratropium bromide impurity B
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(1R,3r,5S,8s)-3-[[(2RS)-3-Hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₂₀H₃₀BrNO₃

Numéro CAS:

58073-59-9

Poids moléculaire :

412.36

Code UNSPSC :

41116107

Nomenclature NACRES :

NA.24

Produits recommandés

Slide 1 of 10

1 of 10

Y0000276

Ipratropium impurity A

BP930

Ciprofloxacin impurity standard

USP

1347529

Ipratropium bromide Related Compound B

USP

1347530

Ipratropium bromide Related Compound C

X0101000

Xylometazoline impurity A

BP626

8s-Isopropyl-3β-hydroxytropanium bromide

Supelco

PHR3017

Ipratropium Bromide Related Compound A

Y0000757

(−)-Riboflavine

USP

1347518

Ipratropium bromide Related Compound A

USP

1492266

Palonosetron Related Compound E

Qualité

pharmaceutical primary standard

Famille d'API

ipratropium

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Étalons de référence analytiques | Sigma-Aldrich

Étalons des instituts de métrologie et des pharmacopées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ipratropium bromide impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

Mention d'avertissement

Warning

Mentions de danger

H302

Conseils de prudence

P264 - P270 - P301 + P312 - P501

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Intranasal ipratropium bromide for the common cold.

Zaina H AlBalawi et al.

The Cochrane database of systematic reviews, 6(6), CD008231-CD008231 (2013-06-21)

The common cold is one of the most common illnesses in humans and constitutes an economic burden both in terms of productivity and expenditure for treatment. There is no proven cure for the common cold and symptomatic relief is the

Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.

Virginia Norris et al.

Pulmonary pharmacology & therapeutics, 26(5), 574-580 (2013-03-26)

There are few data on the bronchodilatory effects of adding short-acting bronchodilators (SABA) to maintenance, long-acting bronchodilator therapy. This study assessed the additional bronchodilation and safety of adding supratherapeutic doses of salbutamol (SALB) or ipratropium bromide (IPR) to the novel

The effect of bronchodilators administered via aerochamber or a nebulizer on inspiratory lung function parameters.

S K Ramlal et al.

Respiratory medicine, 107(9), 1393-1399 (2013-06-19)

In chronic obstructive pulmonary disease (COPD) the clinical efficacy of bronchodilator therapy delivered via a nebulizer versus an aerochamber on FEV1 is controversial. No studies comparing changes in inspiratory pulmonary function parameters (ILPs) using these inhaler devices are currently available.

COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.

Gary T Ferguson et al.

International journal of chronic obstructive pulmonary disease, 8, 139-150 (2013-05-10)

Ipratropium bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant. The objective of this study was to evaluate patient satisfaction, device usage, and long-term safety of CVT-R

Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.

Ralph J Panos

International journal of chronic obstructive pulmonary disease, 8, 221-230 (2013-05-10)

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality and its treatment is critical to improve quality of life, reduce symptoms, and diminish the frequency of COPD exacerbations. Due to the harmful environmental effects of pressurized

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique